Peptides for Alzheimer's disease: the metabolic approach - A Clin...

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Alzheimer's disease involves significant metabolic dysfunction, making peptides that modulate neurotrophic factors and insulin signaling promising therapeutic avenues. Clinicians might consider Cerebrolysin or Dihexa for early-stage patients, carefully monitoring metabolic markers and acknowledging their investigational status.

Peptides for Alzheimer's Disease: The Metabolic Approach

Approximately 6.7 million Americans aged 65 and older are living with Alzheimer's disease (AD) in 2023, a number projected to nearly double by 2050 [1]. While amyloid-beta plaques and tau tangles are hallmarks, the metabolic dysfunction underlying AD, often termed 'Type 3 Diabetes,' is gaining significant clinical attention. This perspective shifts focus from solely clearing protein aggregates to restoring cellular energy balance and insulin sensitivity within the brain. Peptides, with their targeted signaling capabilities, offer a compelling avenue for intervention.

One peptide showing promise in this metabolic context is Dihexa. Derived from angiotensin IV, Dihexa, at doses typically ranging from 10-20 mg orally three times per week, has demonstrated neurotrophic properties in preclinical models. Its mechanism involves enhancing the activity of hepatocyte growth factor (HGF) and its receptor, c-Met, which are critical for synaptogenesis and neuronal survival [2]. In animal models of AD, Dihexa has been shown to improve cognitive function and reduce synaptic loss. The nuance here is that while its neurogenic effects are potent, human trials are still in early stages, and long-term safety data is limited, meaning its use remains off-label and investigational.

Another peptide, Cerebrolysin, a mixture of porcine brain-derived peptides, has been studied extensively, particularly in Europe and Asia, for its neuroprotective and neurotrophic effects. Clinical trials, often using doses of 10-30 mL intravenously daily for 10-20 days, followed by maintenance regimens, have shown modest improvements in cognitive function and global clinical impression in patients with mild to moderate AD [3]. Cerebrolysin's multifaceted action includes modulating neuroinflammation, improving glucose utilization, and stimulating neurogenesis. However, its effectiveness in advanced AD stages is less clear, and its animal origin can be a concern for some patients regarding potential immunological reactions, although this is rare.

Insulin-like growth factor 1 (IGF-1) is a critical regulator of brain glucose metabolism and neuronal health. Reduced IGF-1 signaling is implicated in AD pathogenesis, contributing to insulin resistance and impaired amyloid-beta clearance [4]. While direct systemic IGF-1 administration can have significant side effects, including hypoglycemia and potential oncogenic concerns, intranasal delivery is being explored to bypass peripheral effects and target the brain more directly. Doses of intranasal insulin, which shares signaling pathways with IGF-1, have been studied at 20-40 IU daily, showing some cognitive benefits in early AD [5]. The challenge with intranasal delivery is ensuring consistent brain penetration and avoiding systemic absorption.

Compared to traditional cholinesterase inhibitors like Donepezil, which primarily aim to boost acetylcholine levels, peptides like Dihexa or Cerebrolysin offer a more upstream, disease-modifying approach by addressing fundamental metabolic and neurotrophic deficits. Donepezil, while FDA-approved, often provides only symptomatic relief and doesn't halt disease progression. Many patients experience gastrointestinal side effects, and its efficacy diminishes as the disease advances. For instance, a patient on Donepezil might see a temporary improvement in MMSE scores by 1-2 points, but this rarely translates into significant functional gains in the long run. Peptides, by contrast, aim to restore cellular resilience and improve synaptic plasticity, potentially offering more sustained benefits, though robust long-term human data is still accumulating.

The metabolic approach to AD also considers peptides that influence gut-brain axis health, such as those targeting GLP-1 receptors. GLP-1 receptor agonists, like Liraglutide or Semaglutide, are primarily used for type 2 diabetes and weight management, but emerging research suggests neuroprotective effects. GLP-1 receptors are present in the brain, and activation may improve insulin signaling, reduce neuroinflammation, and promote neuronal survival [6]. While specific peptide analogs for AD are under investigation, clinicians are observing cognitive benefits in diabetic patients on these medications. For example, a patient on Semaglutide 1.0 mg weekly for diabetes might also experience unexpected improvements in cognitive processing speed, indicating a broader systemic effect.

You'll find that managing AD with peptides isn't a one-size-fits-all solution. Patient selection is crucial; individuals in early stages of cognitive decline or those with strong metabolic risk factors (e.g., insulin resistance, obesity) might respond better. A thorough metabolic workup, including fasting insulin, HOMA-IR, ApoE genotyping, and inflammatory markers, is essential before considering these interventions. Combining peptides with lifestyle modifications, such as ketogenic diets or targeted exercise, can synergistically enhance outcomes by further optimizing brain metabolism.

The clinical takeaway: For patients with early Alzheimer's or significant metabolic risk factors, consider a trial of Cerebrolysin at 10-30 mL IV daily for 10-20 days, or explore off-label Dihexa 10-20 mg orally three times weekly, always monitoring for cognitive and metabolic markers like fasting glucose and insulin, while educating patients on the investigational nature and limited long-term safety data.

References